Litcius/Paper detail

Understanding, Verifying, and Implementing Emergency Use Authorization Molecular Diagnostics for the Detection of SARS-CoV-2 RNA

Stephanie L. Mitchell, Kirsten St. George, Daniel D. Rhoads, Susan M. Butler‐Wu, Vaishali Dharmarha, Peggy McNult, Melissa B. Miller

2020Journal of Clinical Microbiology75 citationsDOIOpen Access PDF

Abstract

diagnostic use, assays for the detection of SARS-CoV-2 nucleic acids have emergency use authorization (EUA) from the FDA. Outside of highly specialized academic and commercial laboratory settings, clinical microbiology laboratories are likely unfamiliar with the EUA classification, and thus, assay verification can be daunting. Further compounding anxiety for laboratories are major issues with the supply chain that are dramatically affecting the availability of test reagents and requiring laboratories to implement multiple commercial EUA tests. Here, we describe guidance for the verification of assays with EUA for the detection of SARS-CoV-2 nucleic acid from clinical specimens.

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicMolecular diagnosticsVirologyCoronavirusCoronavirus disease 2019 (COVID-19)Diagnostic testMedicine2019-20 coronavirus outbreakIntensive care medicineDiseaseBiologyInfectious disease (medical specialty)BioinformaticsPathologyEmergency medicineOutbreakSARS-CoV-2 detection and testingSARS-CoV-2 and COVID-19 ResearchCOVID-19 diagnosis using AI